Navigation Links
Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
Date:10/1/2009

PHILADELPHIA, Oct. 1 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical and medical device services company, announces the promotion of its current Chief Operating Officer, Troy W. McCall, Ph.D. to Chief Executive Officer. The appointment is part of the company's longstanding succession plan to support current CEO Dr. Simon Yaxley's desire to transition to an advisory role with the company's Board of Directors as Deputy Chairman.

Michael Barry, Non-Executive Chairman of the Board of Premier Research Group Limited, said, "On behalf of the Board, I would like to thank Dr. Yaxley for his efforts, commitment to excellence, and vision as CEO and Co-founder of Premier Research. Dr. McCall's commitment, drive, and deep understanding of the business make him the ideal successor to ensure that Premier Research maintains its outstanding track record of growth and customer service."

Dr. McCall's move into the CEO role is effective immediately and follows on the heels of nearly three years with the company as COO where he has led the successful integration of four acquisitions, established a global organization, and achieved year on year organic growth in excess of 20%. During Dr. McCall's tenure as COO, the company has initiated support of medical device trials in the U.S., launched a Functional Sourcing group, expanded the company's clinical research sites, and completed the company's first ever NDA submission on behalf a sponsor. Dr. McCall's leadership has firmly established Premier Research as a high quality, full-service, global CRO.

Dr. Simon Yaxley, Deputy Chairman, commented, "It is exciting and rewarding to have Troy stepping into the CEO role. This is what we have been working together towards and he deserves the recognition. I can think of no one more suited to continue to grow this successful company we, and many others, have worked hard to create. I also look forward to my continued involvement in the business as we continue to grow both organically as well as through acquisition."

Dr. McCall stated, "When I joined Premier Research, it was with the primary goal for the company to become the CRO of choice for global pharmaceutical and biotechnology companies. I am proud to say that we have completed several important milestones, and we are well on our way. This would not have been possible without the efforts and contributions of everyone in the organization. I am grateful for those efforts and look forward to continuing to exceed our client's expectations though our focus on operational excellence and unparalleled customer service."

About Premier Research

Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, neuroscience, oncology, and infectious disease and have a wealth of experience in medical device and pediatric research.

Premier Research has 30 offices and operates in more than 30 countries across North America and Europe employing more 1,200 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate, and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.

www.premier-research.com

SOURCE Premier Research Group Limited


'/>"/>
SOURCE Premier Research Group Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Premier Heart Launches Multifunction CardioGram(TM) (MCG) In Latin America and the Caribbean
2. Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
3. Premier Research Announces Milestone Investigational New Drug Application
4. Premier Research Expands its Medical Device Operations to the United States
5. Premier Research Announces Milestone New Drug Application
6. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
7. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Premier Micronutrient Launches Supplement for Hearing Health
10. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
11. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):